SciBX: Science-Business eXchange Contents: January 31 2013, Volume 6 / Issue 4

TABLE OF CONTENTS January 31 2013, Volume 6 / Issue 4 Analysis Cover Story Translational Notes Targets and Mechanisms Public-Private Interface The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Genitourinary disease Infectious disease Inflammation Neurology Various The Distillery: Techniques Drug platforms Assays and screens Disease models Advertisement BioPharma Dealmakers   A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The October 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a focus feature on those active in Neuro-partnering. This week, find out about how you can collaborate with Sanofi Pasteur. New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top CRISPR genome editing Chris Cain doi:10.1038/scibx.2013.77 Five separate research teams have developed a Cas9 endonuclease–based method for sequence-specific genome modification guided by DNA-RNA base pairing. Although the approach is technically more straightforward than existing methods, such as zinc finger nucleases and transcription activator–like effector nucleases, its specificity has yet to be fully determined. Full Text | PDF Translational Notes Top Translational globetrotting Steve Edelson doi:10.1038/scibx.2013.78 Six like-minded translational research centers have partnered to help speed the commercialization of academic research. The international cadre, dubbed the Global Alliance of Leading Drug Discovery and Development Centres, comprises more than 400 drug developers working on at least 165 projects. Full Text | PDF Targets and Mechanisms Top Toll-erating AD Lev Osherovich doi:10.1038/scibx.2013.79 Laval University and GlaxoSmithKline have shown that peripheral administration of the adjuvant MPL can help treat Alzheimer's disease in mice. Although the findings point to a potential immunomodulatory approach for addressing the neurodegenerative disease, the pharma is now focusing on elucidating the mechanism before advancing the program. Full Text | PDF Public-Private Interface Top Evotec's growing Ivy Kai-Jye Lou doi:10.1038/scibx.2013.80 Evotec is double dipping into the Ivy League, this time partnering with Yale University to move early stage research from the university's labs into late preclinical and IND-ready assets for third parties to license. The Yale collaboration is upstream of the biotech's 2011 deal with Harvard University because the projects are not predefined. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Desmoglein 1 (DSG1); DSG3 doi:10.1038/scibx.2013.81 In vitro and mouse studies identified a DSG-binding peptide that could help treat PV. Full Text | PDF Cancer Top NADP-dependent malic enzyme 1 cytosolic (ME1); NADP-dependent malic enzyme 2 mitochondrial (ME2); p53 doi:10.1038/scibx.2013.82 Cell culture and mouse studies suggest inhibiting ME1 or ME2 may help treat cancer. Full Text | PDF NGFI-A binding protein 2 (EGR1 binding protein 2; NAB2); signal transducer and activator of transcription 6 (STAT6) doi:10.1038/scibx.2013.83 Two separate genetic sequencing studies identified a NAB2-STAT6 gene fusion associated with solitary fibrous tumors (SFTs), which could provide a new therapeutic target. Full Text | PDF BCR-ABL tyrosine kinase doi:10.1038/scibx.2013.84 Cell culture and mouse studies suggest the BCR-ABL tyrosine kinase inhibitor GZD824 could help treat imatinib-resistant cancer. Full Text | PDF VEGF doi:10.1038/scibx.2013.85 Mouse and human studies suggest Votrient pazopanib, a VEGF signaling inhibitor, could help improve the efficacy of paclitaxel in anaplastic thyroid cancer. Full Text | PDF Cardiovascular disease Top POU class 1 homeobox 1 (POU1F1; PIT1) doi:10.1038/scibx.2013.86 Cell culture and mouse studies suggest spironolactone could help prevent calcification of vascular and other soft tissues, which is seen in patients who have chronic kidney disease (CKD). Full Text | PDF Endocrine/metabolic disease Top Free fatty acid receptor 1 (FFAR1; GPR40) doi:10.1038/scibx.2013.87 In vitro and mouse studies identified an alkyne series of FFAR1 agonists that could help treat type 2 diabetes. Full Text | PDF Genitourinary disease Top Prolactin releasing hormone receptor (PRLHR; GPR10) doi:10.1038/scibx.2013.88 Patient sample and mouse studies suggest inhibiting PRLHR could help treat uterine fibroids. Full Text | PDF Infectious disease Top Lysine-specific demethylase 4 (KDM4; JMJD2) doi:10.1038/scibx.2013.89 Cell culture and explanted mouse ganglia studies suggest JMJD2 inhibitors could be used to treat primary HSV-1 infection and prevent reactivation. Full Text | PDF Influenza A virus matrix protein 2 (M2) doi:10.1038/scibx.2013.90 In vitro studies identified M2 inhibitors that could help treat amantadine-resistant influenza. Full Text | PDF Inflammation Top Leptin doi:10.1038/scibx.2013.91 Mouse studies suggest anticholinergic compounds could help treat obesity-induced asthma. Full Text | PDF Neurology Top Histone deacetylase 3 (HDAC3) doi:10.1038/scibx.2013.92 Mouse studies suggest HDAC3 inhibition could help treat cocaine addiction. Full Text | PDF Toll-like receptor 4 (TLR4) doi:10.1038/scibx.2013.93 Cell culture and mouse studies suggest moderately agonizing TLR4 could help treat AD. Full Text | PDF Hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN); hypoxia-inducible factor 1α (HIF1A; HIF1α) doi:10.1038/scibx.2013.94 Human and rabbit studies suggest compounds that inhibit HIF-PH could prevent neurogenesis deficits in preterm infants. Full Text | PDF Various Top Caspase recruitment domain family member 15 (CARD15; NOD2) doi:10.1038/scibx.2013.95 Mouse studies suggest intestinal microbiota from organisms with functional NOD2 could help protect against colitis and colitis-associated colorectal cancer. Full Text | PDF Distillery: Techniques Assays and screens Top DNA analysis of Pap smear samples to detect ovarian and endometrial cancer doi:10.1038/scibx.2013.96 DNA sequencing of Pap smear samples could help diagnose ovarian and endometrial cancer. Full Text | PDF Disease models Top Induced pluripotent stem (iPS) cell–derived models of familial hypertrophic cardiomyopathy (HCM) doi:10.1038/scibx.2013.97 Patient-derived iPS cell models of familial HCM could help identify new treatments for the disease. Full Text | PDF td> Mouse model for lymphocytic choriomeningitis virus (LCMV) infection that produces hemorrhagic-like disease doi:10.1038/scibx.2013.98 A new mouse model could be used to screen for therapeutics or test vaccines against arenavirus infections that cause hemorrhagic-like disease. Full Text | PDF Transgenic miniature pig model for hypercholesterolemia and atherosclerosis doi:10.1038/scibx.2013.99 A transgenic miniature pig model for hypercholesterolemia and atherosclerosis could aid the development of imaging technologies, intravascular devices and therapeutics. Full Text | PDF Drug platforms Top Antigen-specific T cells generated from induced pluripotent stem (iPS) cells derived for adoptive immunotherapy doi:10.1038/scibx.2013.100 Two separate groups showed that iPS cells derived from mature CD8+ T cells can be differentiated into antigen-specific T cells that may be useful for overcoming T cell exhaustion during adoptive immunotherapy. Full Text | PDF Clustered, regularly interspaced short palindromic repeats (CRISPR) RNA editing system to modify mammalian DNA doi:10.1038/scibx.2013.101 A CRISPR-derived genome editing system could be used to modify mammalian DNA. Full Text | PDF Sortase-mediated modification of a targeted mAb to improve antigen delivery and presentation doi:10.1038/scibx.2013.102 Sortase-mediated modification of therapeutic mAbs could be useful for developing vaccines and therapeutics to treat viral infections. Full Text | PDF Structure-based design of peptide inhibitors and activators of ubiquitin enzymes doi:10.1038/scibx.2013.103 In vitro studies identified a strategy to develop peptide inhibitors and activators of ubiquitin pathway enzymes that could help treat various diseases. Full Text | PDF Terminally differentiated stem cell–derived cells with negligible immunogenicity doi:10.1038/scibx.2013.104 Terminally differentiated stem cell–derived cells show negligible immunogenicity, suggesting they could be useful for transplant and cell therapy applications. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.